Neurotrope, Inc. Common
NTRP
NTRP was delisted on the 1st of December, 2020.
23 hedge funds and large institutions have $12.7M invested in Neurotrope, Inc. Common in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
39% more capital invested
Capital invested by funds: $9.17M → $12.7M (+$3.58M)
28% more funds holding
Funds holding: 18 → 23 (+5)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NRS
Neville Rodie & Shaw
New York
|
+$1.01M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
+$310K |
| 3 |
Renaissance Technologies
New York
|
+$267K |
| 4 |
TCM
Tanaka Capital Management
New York
|
+$198K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$148K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
-$249K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$43.2K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$11K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.83K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$3.68K |
NTRP Hedge Fund Activity: Q2 2018 in Review
23 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Neurotrope, Inc. Common (NTRP) for Q2 2018, worth a combined $12.7M — up 39% from $9.17M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new NTRP positions and 2 closed out — a net gain of 5 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Neville Rodie & Shaw, opening a new position worth an estimated $1.01M. The largest seller was Pathstone Family Office, exiting entirely with an estimated $249K sold.
- 23 institutional investors held Neurotrope, Inc. Common (NTRP) as of Q2 2018, up from 18 in Q1 2018.
- Funds reported $12.7M of Neurotrope, Inc. Common stock for Q2 2018, up 39% quarter-over-quarter.
- 7 funds opened new Neurotrope, Inc. Common positions in Q2 2018 and 2 closed out, a net change of +5 holders.
- The largest Neurotrope, Inc. Common buyer in Q2 2018 was Neville Rodie & Shaw, an estimated $1.01M added.
- The largest Neurotrope, Inc. Common seller in Q2 2018 was Pathstone Family Office, an estimated $249K sold.
Based on aggregated 13F filings for Q2 2018.